![X-linked retinitis pigmentosa](/sites/default/files/styles/x_large/public/2024-07/johannes-krupinski-eyesight-unsplash.jpg?itok=ttbV-Bm5)
Beacon lights up with $170m for retinal disease gene therapy
UK-headquartered Beacon Therapeutics has raised a whopping $170 million in second-round financing that will be used to advance a gene therapy for an inherited cause of blindness through a p